Compare Abbott Laboratories (ABT) vs Burlington Stores Inc (BURL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Burlington Stores Inc — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Burlington Stores Inc trades at $312.75 (market cap $19.90B). The key difference: Abbott Laboratories is far larger — about 8.4× Burlington Stores Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| ABT | BURL | |
|---|---|---|
Market Cap | $166.94B | $19.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $347.82 |
52-Week Low | $82.57 | $242.43 |
Enterprise Value | $193.69B | $25.02B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Burlington Stores (BURL) trades at $312.36, showing modest daily decline of -0.26% but maintaining strong fundamental performance with consistent earnings beats. The stock exhibits bearish technical signals despite positive analyst sentiment, with 94% buy ratings and a $364.40 consensus price target. Recent Q1 2026 results exceeded expectations with $2.01 EPS versus $1.80 expected, marking the 14th consecutive quarter of double-digit earnings growth.
BURL presents a compelling growth story with expanding margins and store expansion plans, though technical indicators suggest near-term caution. The stock's premium valuation (P/E 32.14) reflects growth expectations, while competitive pressures and consumer spending sensitivity remain key risks. Upside potential exists toward analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
